SIX1 and breast carcinoma: Studies have shown that the increased expression of SIX1 in tumors, such as in hepatocellular carcinoma [30], breast cancer [31], and colorectal cancer [32], often indicates poor clinical outcomes and promotes tumor proliferation, invasion, and metastasis.